-
In this issue: Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions.
-
Researchers from duke university and the university of California, San Francisco enrolled 40 patients with symptoms of overactive bladder (OAB), i.e., urgency, frequency, and/or urge incontinence, and 40 patients with no history of OAB symptoms. The women's view of symptoms and treatments were measured with a utility score.
-
-
Poly(adenosine diphosphate [adp]-ribose) polymerase (PARP) is an enzyme participating in low-fidelity DNA repair of single strand breaks. Pharmacologic inhibition of PARP has shown to be effective in tumors lacking homologous recombination, such as those harboring silencing mutations of BRCA1 and 2.
-
To provide guidance to clinicians on the use of hormone replacement therapy, the authors conducted a systematic review of the randomized, placebo-controlled trials of menopausal hormone therapy published in English since 2002 that assessed primary prevention of chronic conditions.
-
Patients who received treatment for depression within a year were identified in a Japanese database of more than 323,000 patients. The investigators asked 2354 patients to complete a questionnaire on depression with a specific focus on patient-physician relationships.
-
In this issue: Side effects of finasteride; new ruling on pharmaceutical companies paying generic manufacturers; and FDA actions.
-
Several studies have implicated endometriosis as a risk factor for the subsequent development of invasive epithelial ovarian cancer.
-
Results of primary studies on and meta-analyses of the effects of vitamin D therapy on fracture risk have failed to conclusively demonstrate benefit.
-
Through the contraceptive choice project, the authors performed a prospective cohort study in which 9256 women living in the region surrounding St. Louis, Missouri, received a reversible contraceptive method of their choice for up to 3 years at no cost.
